Kuhadiya ND, et al. - In this retrospective analysis, researchers tested the premises that, in C-peptide-positive patients with type 1 diabetes (T1D), a chronic disease characterized by autoimmune destruction of the pancreatic β cells, the addition of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to insulin would result in a reduction in glycated haemoglobin (HbA1c) with reduced insulin requirements and an increase in C-peptide concentrations. The study sample consisted of 11 normal-weight subjects with T1D consecutively treated with a GLP-1RA in addition to insulin. According to findings, the addition of GLP-1RA insulin therapy in normal-weight T1D patients resulted in a reduction in HbA1c with reduced insulin requirements, a 3.5-fold increase in C-peptide concentrations, and insulin-free treatment in 50% of patients who tolerated GLP-1RA therapy over a 12 ± 1 week period.